A Predictive Nomogram for Short-Term Outcomes of Myasthenia Gravis Patients Treated With Low-Dose Rituximab
Source : https://pubmed.ncbi.nlm.nih.gov/38739094/
The nomogram achieved an optimal prediction of short-term outcomes in patients treated with low-dose rituximab.
A shorter disease duration, a positive anti-MuSK antibody, and the AA genotype in FCGR2A rs1801274 were significant predictors for achieving clinical response within 6 months when treated with rituximab 600 mg.
Myasthenia Gravis-Like Syndrome Resulting From Immune Checkpoint Inhibitors in a Patient With Urothelial Carcinoma
The widespread use of immune checkpoint inhibitors (ICIs) for the treatment of various types of cancer has led to increasing reports of associated adverse effects. The use of the ipilimumab/nivolumab/sacituzumab...
The authors describe a rare case of treatment with ipilimumab, nivolumab, and sacituzumab that induced a myasthenia gravis-like syndrome and caused severe, multisystem autoimmune-like toxicity.
The study revealed a high sensitivity of 88% for repetitive ocular vestibular-evoked myogenic potentials in ocular myasthenia gravis, but specificity and PPV were too low to allow for the ocular myasthenia gravis diagnosis as a single test.
Advances in Understanding and Managing Myasthenia Gravis: Current Trends and Future Directions
Myasthenia gravis (MG) is an autoimmune illness characterized by autoantibodies against the acetylcholine receptor (AChR), muscle-specific tyrosine kinase (MuSK), and an increasing number of extra postsynaptic proteins. Pathogenic autoantibodies reduce...
Treatment and management for MG involve removing autoantibodies from circulation or blocking effector mechanisms using techniques such as complement inhibition, plasmapheresis, and B-cell elimination.
An Exploration of Causal Relationships Between Nine Neurological Diseases and the Risk of Breast Cancer: a Mendelian Randomization Study
Source : https://www.aging-us.com/article/205745/text
Background: Some preceding researches have observed that certain neurological disorders, such as Alzheimer's disease and multiple sclerosis, may affect breast cancer risk. However, whether there are causal relationships between these...
There was no evidence that myasthenia gravis could significantly affect an overall breast cancer risk.